The US Food and Drug Administration has been rapidly approving new checkpoint inhibitors and targeted therapies for melanoma and other tumors. (cancernetwork.com)
Thomson Reuters has selected Neota Logic to provide interactive decision tools for the company's new Checkpoint Catalyst service for tax professionals. (neotalogic.com)
Scientists have long sought a way to discover whether patients will respond to new checkpoint inhibitor immunotherapies and to better understand the characteristics that indicate a tumor can be successfully treated with them. (sciencedaily.com)